Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Focus Graphite is Developing a Mine in a High Demand Resource Sector

Interview with President & COO Don Baxter at the Mines & Money 2014 in London Symbol: V.FMS
Commodity-TV | June 8, 2018 |

Why This Well-Timed Strategy is Forcing Them to Re-evaluate a Junior Oil Play in Texas

By Prodigy NewsG2 Energy Corp. is a Canadian, publicly-traded company (CSE:GTOO,OTCQB:GTGEF, FKN:UD9) focused on identifying and developing OVERLOOKED opportunities in the energy sector.The...
Research | July 14, 2022 |

New proposal puts Macarthur Minerals’ (ASX:MIO) rail link on track

Macarthur Minerals (MMS) has received a key proposal, regarding its planned rail link at the Lake Giles Iron Project in Western Australia’s Yilgarn Region Through the proposal, Macarthur Minerals and Arc Infrastructure will begin developing a commerc...
Joshua Peach | July 16, 2020 |

Blue Sky Diligently Developing 'One of the Most Economic and Leveraged Uranium Plays in the Industry

The Critical Investor sits down with Nikolaos Cacos, president and CEO of Blue Sky Uranium, to discuss recent developments at the company's uranium project in Argentina. Ivana deposit; Rio Negro province, Argentina After raising C$0.87 milli...
Streetwise Reports | February 20, 2020 |

A New Frontier in Psychedelic Therapeutics

Cybin X Kernel "A New Frontier in Psychedelic Therapeutics" About the partnership: Cybin Corporation ( N.CYBN , Forum ) will leverage Kernel’s Flow to quantify brain activity during psychedelic experiences in re...
Featured Submission | January 11, 2021 |

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News

Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. Early this morning, clinical-stage biopharmaceutical company Alder BioPharmaceu...
Streetwise Reports | September 17, 2019 |

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. This morning clinical-stag...
Streetwise Reports | November 19, 2019 |

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data

EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. ...
Streetwise Reports | November 25, 2019 |

Leap Therapeutics Lunges Forward on $132M Licensing Deal and $27M Equity Raise

Shares of Leap Therapeutics jumped 60% after the company reported that it signed an exclusive option and license agreement for its immuno-oncology drug DKN-01 with BeiGene in the Asia Pacific region excluding Japan. The firm also secured an additional $27 million in equity fin...
Streetwise Reports | January 6, 2020 |
1 2 3 4 5 6 7 8 9 10 ...